UPC Case Law
Meril Italy Srl and others v Edwards Lifesciences Corporation
Decision of the UPC Court of Appeal of 25 November 2025, UPC CoA 464/2024
UPC Case Law by Pitch, edited by Bart Lieben · Published
TL;DR
The Court of Appeal upheld EP 3 646 825 as amended by Auxiliary Request II and confirmed that Meril's Myval Octacor heart valve system infringes it. The Court modified the injunction only to let XL valves reach patients for whom a physician confirms they are the only treatment option, and it cut the interim payment to €363,000. The decision sets out the UPC's own approach to inventive step, the default rule on permanent injunctions, and a 50% cap on interim awards of representation costs.
Key holding
Inventive step under Art 56 EPC is assessed by identifying the objective problem, which must contain no pointer to the solution. The court then asks whether the skilled person, starting from any realistic starting point, would (not merely could) have arrived at the claimed solution, prompted by a pointer or as a matter of routine. Where infringement is found, the Court shall order a prohibition under Art 63(1) UPCA unless there are special reasons, such as disproportionality under Art 3 of the Enforcement Directive, and the interests of third parties such as patients may be weighed. As a general rule, Art 69(1) UPCA and R 150(2) RoP do not allow an interim reimbursement of more than 50% of the recoverable-costs ceiling.
Questions decided
- When are entities the "same parties" under Art 33(4) second sentence UPCA?
- How far does the Court of Appeal review admission of subsequent patent amendments?
- Can an embodiment in the specification fall outside the claims?
- What is the UPC's approach to inventive step?
- Can patient interests limit a permanent injunction and corrective measures?
- What is the maximum interim award of representation costs?
Full summary
Read the full analyses for free — create a free account
With a free Academy account you read the full analysis of every Court of Appeal decision: the facts and procedure, the issues, the court’s reasoning and the practice points. Your name, an e-mail address and a password; no payment, and you can delete the account yourself at any time.
In the same case
- Decision · UPC CoA 635/2024
Meril GmbH v Respondent 1 and SWAT Medical AB
The Court of Appeal set aside a Paris Central Division order that had given a European patent attorney and his company access to all pleadings and evidence in a revocation counterclaim.
- Order · UPC CoA 166/2025
Meril GmbH and others v Edwards Lifesciences Corporation
The Court of Appeal refused Meril's request to suspend the Munich Local Division's infringement decision in favour of Edwards Lifesciences pending Meril's appeal.
- Order · UPC CoA 634/2024
Meril Italy S.r.l. v SWAT Medical AB and another
A lawyer or European Patent Attorney who is personally a party before the UPC cannot represent themselves.
- Order · UPC CoA 635/2024
Meril GmbH v SWAT Medical AB and another
A lawyer or European Patent Attorney who is personally a party before the UPC must still be represented by someone else.
- Order · UPC CoA 636/2024
Meril Life Sciences Pvt. Ltd v Respondent 1 and SWAT Medical AB
A lawyer or European Patent Attorney who is a party before the UPC cannot represent himself and must instruct a separate authorised representative.
More on validity and revocation
- Order · UPC CoA 176/2026
Netflix Services Germany GmbH and others v DivX, LLC
The Court of Appeal refused Netflix's request for suspensive effect against the Munich Local Division's infringement decision in favour of DivX, even though the EPO Opposition Division revoked the patent after that decision.
- Decision · UPC CoA 935/2025
Appellant (name not stated) v Amycel, LLC
The Court of Appeal set aside a decision by default of The Hague Local Division and allowed the defendant's application to have it set aside under R 356 RoP.
- Order · UPC CoA 145/2026
Barco N.V. v Yealink (Xiamen) Network Technology Co., Ltd. and others
The Court of Appeal upheld the Brussels Local Division's refusal to let Barco add a late auxiliary request (AR6) whose claim 1 is identical to dependent claim 9, a claim neither asserted for infringement nor attacked in the counterclaim for revocation.